Results 51 to 60 of about 154,391 (307)

Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1

, 2012
Loss of the tumor suppressor Pdcd4 was reported for various tumor entities and proposed as a prognostic marker in tumorigenesis. We previously characterized decreased Pdcd4 protein stability in response to mitogenic stimuli, which resulted from p70S6K1 ...
Bernhard Brüne, Milke, Larissa, Kathrin Schulz, Larissa Milke, Heidi R Bokesch, Schulz, Kathrin, Colburn, Nancy H., Blees, Johanna, Schmid, Tobias, Curtis J. Henrich (131182), Tobias Schmid, Kathrin Schulz (131170), Magdalena M. Bajer (131176), Heidi R. Bokesch (131163), Bajer, Magdalena M., Daniela Rübsamen (131166), Johanna S Blees, Henrich, Curtis J., Nancy H. Colburn (131186), James B McMahon, Magdalena M Bajer, James B. McMahon (7677), McMahon, James B., Daniela Rübsamen, Kirk R. Gustafson (131179), Tobias Schmid (131190), Nancy H Colburn, Brüne, Bernhard, Kirk R Gustafson, Rübsamen, Daniela, Bernhard Brüne (131193), Curtis J Henrich, Bokesch, Heidi R., Gustafson, Kirk R., Larissa Milke (131173), Johanna S. Blees (131161)   +35 more
core   +1 more source

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter [PDF]

, 2010
The cytokine TGF-beta acts as a tumor suppressor in normal epithelial cells and during the early stages of tumorigenesis. During malignant progression, cancer cells can switch their response to TGF-beta and use this cytokine as a potent oncogenic factor;
Hiller, L, Monteverde, M, Louise Hiller, Shah, Reshma, Kalna, G., Karin A. Oien, Jonathan A. Cooper, Maurer, M.E., O'Brien, Darren I, Jelena Mann, Oien, KA, Frame, MC, Frame, Margaret C., David C. K. Chu, Crook, T., Chu, David C K, Lo Nigro, Cristiana, Lattanzio, L., Orange, Clare, Spender, Lindsay C., Chu, D.C.K., Thurlow, JK, Thurlow, Johanna K., Shah, R, Linda J. Nicholson, Syed, Nelofer, Harris, Adrian L, Orange, Cl., O'Brien, Darren I., Maurer, Meghan E., Shah, R., Nicholson, LJ, Hiller, Louise, Cooper, J.A., Inman, GJ, Monteverde, M., O'Brien, DI, West, CM, Mann, Jelena, Inman, Gareth J., Harris, AL., Syed, N, Cristiana Lo Nigro, Buffa, FM, Darren I. O’Brien, West, CML, Gasco, Milena, Smith, P, Crook, Tim, Monteverde, Martino, Meghan E. Maurer, Buffa, Francesca M., Kalna, Gabriela, O Brien, DI, Patridge, Max, Hannigan, A., Patridge, M., Paul Smith, Francesca M. Buffa, Cooper, Jonathan A, Mann, J, Oien, Karin A, Crook, T, Spender, Lindsay C.; id_orcid, Reshma Shah, Smith, Paul J., Lattanzio, L, Orange, C, Catharine M. L. West, Kalna, G, Cooper, JA, Max Patridge, Smith, Paul, Johanna K. Thurlow, Margaret C. Frame, Nicholson, Linda J., O'Brien, D.I., Spender, LC, and Gareth J. Inman, Buffa, Francesca M, O'Brien, Darren I., West, Catharine M L, Herrera, Blanca, Gasco, M., Adèle Hannigan, Smith, P., Frame, MC., Milena Gasco, Lo Nigro, C., Inman, Gareth J, Herrera, B, Oien, K.A., Frame, Margaret C, Laura Lattanzio, Gabriela Kalna, West, Catharine M. L., Nicholson, Linda J, Tim Crook, West, C.M.L., Nelofer Syed, Chu, DCK, Blanca Herrera, West, Catharine M L; id_orcid, Hannigan, Adèle, Thurlow, Johanna K, Chu, DC, Mann, J., Spender, Lindsay C, Gasco, M, Clare Orange, Martino Monteverde, Patridge, M, Buffa, F.M., Maurer, Meghan E, David C.K. Chu, Chu, David C. K., Nicholson, L.J., Harris, AL, Spender, L.C., Lindsay C. Spender, Catharine M.L. West, Herrera, B., Hannigan, A, Maurer, ME, Cooper, Jonathan A., Oien, Karin A., Lo Nigro, C, Adrian L. Harris, Inman, G.J., Gareth J. Inman, Harris, Adrian L., Thurlow, J.K., Syed, N., Lattanzio, Laura   +133 more
core   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Cell-to-cell transmission of p53 aggregates: a novel player in oncology?

Molecular & Cellular Oncology, 2021
The mutants of the tumor suppressor protein p53 form protein aggregates. It has been proposed that these aggregates propagate like prions, albeit the detailed mechanism of the propagation is unclear.
Naoyuki Iwahashi, Midori Ikezaki, Hiroyuki Saito, Kenji Uchimura, Kazuchika Nishitsuji   +4 more
doaj   +1 more source

p66α Suppresses Breast Cancer Cell Growth and Migration by Acting as Co-Activator of p53

Cells, 2021
p66α is a GATA zinc finger domain-containing transcription factor that has been shown to be essential for gene silencing by participating in the NuRD complex. Several studies have suggested that p66α is a risk gene for a wide spectrum of diseases such as
Qun Zhang, Yihong Zhang, Jie Zhang, Dan Zhang, Mengying Li, Han Yan, Hui Zhang, Liwei Song, Jiamin Wang, Zhaoyuan Hou, Yunhai Yang, Xiuqun Zou   +11 more
doaj   +1 more source

Dissection of the functional interaction between p53 and the embryonic proto-oncoprotein PAX3

, 2007
Studies from murine embryogenesis and cancer cells derived from human melanomas have identified a critical role for the transcription factor PAX3 in the suppression of p53 protein accumulation and p53-dependent apoptosis.
Underwood, Timothy J., Jay Amin, Amin, Jay, Blaydes, Jeremy P., Timothy J. Underwood, Lillycrop, Karen A., Jeremy P. Blaydes, Karen A. Lillycrop   +7 more
core   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

A Second Career for p53 as A Broad-Spectrum Antiviral?

Viruses, 2023
As the world exits the global pandemic caused by the previously unknown SARS-CoV-2, we also mark the 30th anniversary of p53 being named “molecule of the year” by Science based on its role as a tumor suppressor.
Joe B. Harford
doaj   +1 more source

Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways

, 2013
The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known ...
Ashcroft, M, Carroll, VA, Selvarajah, J, Moumen, A, Nathawat, K   +4 more
core   +1 more source

Fos co-operation with PTEN loss elicits keratoacanthoma not carcinoma due to p53/p21^WAF-induced differentiation triggered by GSK3b inactivation and reduced AKT activity [PDF]

, 2008
To investigate gene synergism in multistage skin carcinogenesis, the RU486-inducible cre/lox system was employed to ablate PTEN function [K14.cre/D5PTENflx] in mouse epidermis expressing activated v-fos [HK1.fos].
Chan, W-C., Wu, H., Weng-Chyn Chan, Alexander, C.L., Yao, D., Claire L. Alexander, Jean A. Quinn, Hong Wu, David A. Greenhalgh, Greenhalgh, D.A., Quinn, J., Denggao Yao   +11 more
core   +1 more source